Is The Non-compete Clause For Cross-border Deals In India A Burden Or A Boost?
This article was originally published in PharmAsia News
Deal makers are cautiously viewing the fallout of a recent government statute to prevent non-compete clauses in cross-border deals for existing Indian companies except in special circumstances. Experts await clarification on the statute but some say the new norm will impede deals and affect valuations.
You may also be interested in...
MUMBAI - The Indian government has decided to route all foreign direct investments in existing Indian companies via the Foreign Investment Promotion Board, a surprising move that could have far-reaching implications on big ticket M&As in the country's pharmaceutical industry
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.